Conclusions

Strategists worldwide believe technology has the potential to promote quality, safety and efficiency in shared care, where organisational, social and technical issues are addressed. However, evidence of hospital pharmacists’ views, their perceptions of eHealth and shared care, organisational development and training needs remain under-researched.

References


No conflict of interest.

DGI-002 ADRENAL INSUFFICIENCY INDUCED BY A CHINESE HERBAL MEDICINE
doi:10.1136/ejhp-2013-000276.235

M Kieran, 3C Gavin, 3L O’Shea, 3J Brady, 3C Meegan. Mater Misericordiae University Hospital, Pharmacy Department, Dublin, Ireland (Rep.); 3Mater Misericordiae University Hospital, Department of Endocrinology, Dublin, Ireland (Rep.); 3Mater Misericordiae University Hospital, Biochemistry Department, Dublin, Ireland (Rep.)

Background

Chinese herbal medicines have a history, dating back to 1974, of containing strong prescription drugs [1]. In the United States (US), Food and Drug Authority (FDA) analysis of Chinese herbal preparations has found prednisolone, diazepam, paracetamol, indomethacin and hydrochlorothiazide [1].

During a routine review for type 2 diabetes, a MMUH patient reported new-onset fatigue. In view of the presenting complaint, a Synacthen test and thyroid function tests were performed. The patient’s Synacthen test reported positive for adrenal insufficiency, despite an absence of other clinical symptoms. Repeat testing and external analysis confirmed the result.

Potential causes of the positive Synacthen test were investigated. On further questioning the patient admitted to taking a ‘vitamin-type’ tablet, which was a Chinese herbal medicine, Cow’s Head Brand, Tung Shueh Pills. It was a suspected that the Tung Shueh Pills may have contained corticosteroids, which suppressed the patient’s endogenous corticosteroid production, producing a positive Synacthen test.

Purpose

To find out whether Cow’s Head Brand, Tung Shueh Pills contained corticosteroids.

Materials and Methods

Literature review for reports on Cow’s Head Brand, Tung Shueh Pills.

Analysis of Cow’s Head Brand, Tung Shueh Pills in collaboration with the Irish Medicines Board (IMB)

Results

Cow’s Head Brand, Tung Shueh Pills manufactured by the Ta Ang Pharmaceutical Company are included on a FDA list of herbal preparations has found prednisolone, diazepam, paracetamol, indomethacin and hydrochlorothiazide [1].

During a routine review for type 2 diabetes, a MMUH patient reported new-onset fatigue. In view of the presenting complaint, a Synacthen test and thyroid function tests were performed. The patient’s Synacthen test reported positive for adrenal insufficiency, despite an absence of other clinical symptoms. Repeat testing and external analysis confirmed the result.

Potential causes of the positive Synacthen test were investigated. On further questioning the patient admitted to taking a ‘vitamin-type’ tablet, which was a Chinese herbal medicine, Cow’s Head Brand, Tung Shueh Pills. It was suspected that the Tung Shueh Pills may have contained corticosteroids, which suppressed the patient’s endogenous corticosteroid production, producing a positive Synacthen test.

Purpose

To find out whether Cow’s Head Brand, Tung Shueh Pills contained corticosteroids.

Materials and Methods

Literature review for reports on Cow’s Head Brand, Tung Shueh Pills.

Analysis of Cow’s Head Brand, Tung Shueh Pills in collaboration with the Irish Medicines Board (IMB)

Results

Cow’s Head Brand, Tung Shueh Pills manufactured by the Ta Ang Pharmaceutical Company are included on a FDA list of products that require detention when being imported into the US [1]. The average viral load was 1.9 × 1010 IU/ml and 40% of the patients had more than 600,000 IU/ml HCV RNA. The META VIR liver fibrosis stage was F3–F4 in 36.6% of patients. 62.5% (50/80) achieved SVR, 72.0% in those with genotype 2–3 and 60.8% in 1–4. RVR was achieved in 31.7% of patients with genotype 1–4, and 73.9% in genotype 2–3. 69.2% of patients with genotype 1–4 achieved a complete EVR versus 92.3% in 2–3. 11.5% of patients with genotype 1–4 and 7.7% of those with 2–3 achieved a partial EVR. Relapse rates (18.2%) were lower in genotype 2–3 than in 1–4 (75% of them).

Conclusions

The overall SVR rates observed were in accordance with published data, as well as the higher proportion of patients with genotype 2–3 that achieved a RVR and the highest rate of relapse observed in those with genotype 1–4.

No conflict of interest.

DGI-004 ANALYSIS OF CONSULTATIONS MADE BY PATIENTS IN AN OUTPATIENT SERVICE
doi:10.1136/ejhp-2013-000276.270

I Yeste Gomez, V Escudero Vilaplana, I Marquinez Alonso, C Rodriguez Gonzalez, P Arribal Duran, B Marzal Alfaro, M Sanjurjo Saez. Hospital General Universitario Gregorio Marañón, Pharmacy, Madrid, Spain

Background

Hospital pharmacists interview all outpatients with a prescription, as well as the higher proportion of patients with genotype 2–3 that achieved a RVR and the highest rate of relapse observed in those with genotype 1–4.

No conflict of interest.

DGI-003 ANALYSIS OF CLINICAL EFFECTIVENESS OF TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C MONO-INFECTED PATIENTS
doi:10.1136/ejhp-2013-000276.269

I Larrodé, H Navarro, R Huarte, A Escolano, O Pascual, P Casajús, R Abad. Servet Pharmacy, Zaragoza, Spain

Background

PEGylated interferon (Peg-INF) in combination with ribavirin (RBV) is currently the gold standard treatment in chronic hepatitis C (HCV) patients, achieving viral eradication in approximately 50–60% of patients in published data.

Purpose

To assess the clinical effectiveness of Peg-INF plus RBV for the treatment of chronic HCV mono-infected patients.

Materials and Methods

Retrospective observational study involving 152 patients treated from October 2006 to July 2010. We collected demographic data (age, gender), laboratory reports (genotype, viral load), clinical characteristics, type of Peg-INF and RBV doses. The primary end point was a sustained virological response (SVR). Secondary end points included rapid virological response (RVR), early virological response (EVR) (complete or partial), final viral response (FVR) and virological relapse. Exclusion criteria were: confection, haemodialysis and patients with insufficient data to analyse. Data were obtained from the pharmacy database and medical records.

Results

152 patients (mean age 46 years) were analysed and 84 were included. 65.5% were male. 67.1% with genotype 1–4. 51.2% with genotype 2–3 achieved a partial EVR. Relapse rates (18.2%) were lower in genotype 2–3 than in 1–4 (75% of them).

Conclusions

The overall SVR rates observed were in accordance with published data, as well as the higher proportion of patients with genotype 2–3 that achieved a RVR and the highest rate of relapse observed in those with genotype 1–4.

No conflict of interest.
Purpose The objective of this work was to evaluate the features of consultations made by patients in these situations.

Materials and Methods Observational prospective study performed in all outpatients who demanded an interview with the pharmacist from 01/03/12 to 31/05/12. Data collected: sex, age, pathology, type of question, resolution (yes/no), and whether the patient was sent to another health professional or not.

Results 48 patients were included (56.25% male; mean age 47.25 years). Pathology: 29 HIV; 4 hepatitis C; 3 multiple sclerosis; 3 hepatitis B, and 9 others (one each): lung cancer, renal impairment, rheumatoid arthritis, multiple myeloma, myosarcoma, growth disorder, pulmonary hypertension, glaucoma, and aspergillosis infection. Consultations were classified into 9 types showing in brackets the number of each: 1-Drug-drug interactions (14); 2-Apply for extra medication (9); 3-Side effects (8); 4-Dosage and administering(6); 5-Missed or wrong doses(6); 6-Prescription renewal(2); 7-Maximum dosage(1); 8-Miscalculations(1); 9-Misunderstanding medical prescription(1). Forty-three consultations were solved by the pharmacist (89.58%). In the other 5 cases, patients were sent to the physician: two were taking the treatment incorrectly and needed a special check, two needed to renew the prescription and one was suffering severe side effects.

Conclusions The most common consultations were related to pharmacology except for 18.75% of patients who applied for extra medication (often not possible because of the hospital policy). The pharmacist was able to solve almost 90% of consultations, sending the patients to their doctors just in cases where their health was compromised or new prescriptions were needed.

No conflict of interest.

DGI-005 ANALYSIS OF LEVOFLOXACIN USE IN GERIATRIC UNITS AT A UNIVERSITY HOSPITAL

C Lebaudy, F Chautant, I Bourgeois, F Boye, S Gerard, B Vellas, P Cestac. University Hospital, Geriatric Department, Toulouse, France

Background Overuse of antibiotics, such as fluoroquinolones and third-generation cephalosporins, is a major cause of the emergence of extended-spectrum beta lactamase producing enterobacteriaceae. The use of levofloxacin in elderly inpatients is widespread.

Purpose We investigated the conditions in which this drug was prescribed.

Materials and Methods From 1st January to 31st March 2012, information was recorded on every new levofloxacin prescription from the geriatric units: indication, dose, duration, patient’s medical history, renal function and previous antibiotic. In parallel, levofloxacin consumption was assessed and expressed in terms of the number of Defined Daily Doses (DDD) per 1000 patient-days (PD). The consumption was compared with the data from the French antibiotic network “RAISIN”.

Results 87 patients had a levofloxacin prescription: 55% for community-acquired pneumonia, 20% for nursing-associated pneumonia, 16% for nosocomial pneumonia, and 9% for others indications. 77% of the patients had previously received another antibiotic (47 amoxicillin/clavulanic acid, 20 ceftriaxone). Among patients without signs of gravity (tachycardia, tachypnea, hypotension), 1 in every 2 received levofloxacin associated with ceftriaxone, although this combination is only for intensive care patients according to the French Society of Infectious Diseases. The mean duration of treatment was 10 days. In 1 in every 2 cases, dosage was too high according to the renal function. As a result, the exposure to levofloxacin was 49 DDD per 1000 PD in acute-care units, and 37 DDD per 1000 PD in skilled units. These results are 4 to 7 times higher than those recorded in the “RAISIN” network. For 20% of the patients, levofloxacin was ineffective and another line of antibiotic was prescribed.

Conclusions Our results suggest that to reduce exposure to fluoroquinolones we should avoid systematic association with ceftriaxone, prescribe levofloxacin as the second line after amoxicillin/clavulanic acid and reduce dose and duration.

No conflict of interest.

DGI-006 ANALYSIS OF SAVINGS IF THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP) IS SWITCHED

E Doglianì, F Ferroni, FG De Rosa, F Cattel, G Rainieri, M Abrate, M Paire. ‘Scuola di Specializzazione in Farmacia Ospedaliera, Università degli Studi di Torino, Cuneo, Italy; *Ospedale Amedeo di Savoia, S.C. Infettivologia, Torino, Italy; **ATO San Giovanni Battista – Molinette, S.C.Farmacista, Torino, Italy; *ASO S.Croce e Carle, S.C. Malattie Infettive e Tropicali, Cuneo, Italy, *ASO S.Croce e Carle, S.C. Farmacista, Cuneo, Italy; **ASL CN1, S.C.Farmacist Territoriale, Cuneo, Italy

Background Levofloxacin exhibits excellent bioavailability as well as pharmacokinetic equivalence between the oral and the parenteral form and is one of the medicines most used in the treatment of CAP.

Purpose The purpose of this study is to evaluate the savings that may be achieved by treating patients affected with CAP with sequential treatment (switching from intravenous to oral treatment).

Materials and Methods Both the cost and duration of treatment with levofloxacin were considered. The cost was given by: unitary cost of levofloxacin, cost of the nursing staff, cost of the material for parenteral infusion, cost of the hospitalisation. The duration was considered to be 5 days for patients without complications, 20 days for patients with complications and 10 days as the average in common clinical practise. This model was applied to reality in the S.C. Pneumologia of the ASO S. Croce and Carle of Cuneo. The patients hospitalised for CAP and treated with levofloxacin were individualised through the A.S.400 computerised applications.

Results In 2011 351 patients were hospitalised and treated with levofloxacin tablets and/or vials in the Pneumology ward, 90% of them were suffering from CAP.

For 10 days of treatment the sequential treatment would enable savings equal to 85€/patient. This saving would allow us to treat 12 more patients in a switched treatment regime. For 20 days of treatment the difference would be equal to 205€/patient quantifiable as 14 more patients with CAP treated in hospital without affecting the budget.

Conclusions Oral treatment, as it is equally effective, turns out to be the best therapeutic alternative in terms of savings. In future we will analyse the discharge letters of these patients under the model used in this study, thus assessing the real savings.

No conflict of interest.

DGI-007 ANALYSIS OF THE PRESCRIPTIONS OF ANTIBIOTICS AS LAST RESORT

A Charuel, J Salles, P Gayot, M Legrand-Thapthimdoem. Centre Hospitalier de Mayotte, Mayotte, Mamoudzou, France

Background The composite index on proper use of antibiotics (ICATB) includes surveillance of the ATBs used, evaluation of ATB prescriptions and the existence of an ATB list associated with checking dispensing with limited duration.

Purpose To examine the conformity of ATBs as last resort prescriptions and to promote their proper use.

Materials and Methods From 1988 prescriptions emanating from 7 units were investigated between 2009 and 2011, by taking into account 7 criteria: re-evaluation of the need to continue the treatment, conformity with administrative (AR), clinical/biological (CR), pharmaceutical (PR) requirements, the relevance of the
DGI-004 Analysis of Consultations Made by Patients in an Outpatient Service

I Yeste Gomez, V Escudero Vilaplana, I Marquinez Alonso, C Rodriguez Gonzalez, P Arrabal Duran, B Marzal Alfaro and M Sanjurjo Saez

Eur J Hosp Pharm 2013 20: A96-A97
doi: 10.1136/ejhpharm-2013-000276.270

Updated information and services can be found at:
http://ejhp.bmj.com/content/20/Suppl_1/A96.3

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

- Drugs: gastrointestinal system (278)
- Pulmonary hypertension (7)
- Competing interests (ethics) (1710)
- Drugs: cardiovascular system (351)
- Lung cancer (oncology) (37)
- Lung cancer (respiratory medicine) (37)
- Connective tissue disease (66)
- Degenerative joint disease (59)
- Drugs: CNS (not psychiatric) (393)
- Immunology (including allergy) (615)
- Infectious diseases (417)
- Liver disease (121)
- Multiple sclerosis (44)
- Musculoskeletal syndromes (98)
- Ophthalmology (57)
- Rheumatoid arthritis (47)
- Sexual health (157)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/